Drug Information

Drug General Information
Drug ID
D0G0TS
Former ID
DCL000163
Drug Name
Meclinertant
Synonyms
Reminertant; SR 48692; SR48692; SR-48692; 2-(((1-(7-Chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl)carbonyl)amino)tricyclo(3.3.1.1(sup 3,7))decane-2-carboxylic acid; 2-((1-(7-Chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)pyrazol-3-yl)carbonylamino)tricyclo(3.3.1.1.(3.7))decan-2-carboxylic acid;2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid
Drug Type
Small molecular drug
Indication Inflammatory bowel disease [ICD9: 555, 556; ICD10:K50, K51] Phase 2/3 [521800], [538961]
Therapeutic Class
Anticancer Agents
Company
Sanofi-aventis
Structure
Download
2D MOL

3D MOL
Formula
C32H31ClN4O5
InChI
InChI=1S/C32H31ClN4O5/c1-41-27-4-3-5-28(42-2)29(27)26-16-24(36-37(26)25-8-9-34-23-15-21(33)6-7-22(23)25)30(38)35-32(31(39)40)19-11-17-10-18(13-19)14-20(32)12-17/h3-9,15-20H,10-14H2,1-2H3,(H,35,38)(H,39,40)
InChIKey
DYLJVOXRWLXDIG-UHFFFAOYSA-N
PubChem Compound ID
119192
PubChem Substance ID
7980660, 10238378, 12014763, 14838157, 14862471, 29300128, 47359873, 48253930, 50068556, 52723268, 57339365, 85210068, 103593304, 104102755, 104407741, 113635342, 124950704, 127805129, 134223938, 134338840, 134345994, 135073852, 135651079, 136946549, 144240236, 152343782, 162011729, 162223896, 164045833, 164166845, 174527563, 177749793, 179149953, 198956518, 223704930, 227839908, 241376604, 249617961, 252157483, 252159918, 252216334, 252552607
Target and Pathway
Target(s) Neurotensin receptor type 1 Target Info Antagonist [536827], [536871], [537002]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Reactome Peptide ligand-binding receptors
G alpha (q) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
Peptide GPCRs
GPCR ligand binding
GPCR downstream signaling
GPCRs, Other
References
Ref 521800ClinicalTrials.gov (NCT00290953) Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide. U.S. National Institutes of Health.
Ref 538961(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1582).
Ref 536827High-affinity neurotensin receptor is involved in phosphoinositide turnover increase by inhibition of sodium pump in neonatal rat brain. Neurochem Res. 2008 Nov;33(11):2206-13. Epub 2008 Aug 29.
Ref 536871Stimulation by neurotensin of dopamine and 5-hydroxytryptamine (5-HT) release from rat prefrontal cortex: possible role of NTR1 receptors in neuropsychiatric disorders. Neurochem Int. 2008 Dec;53(6-8):355-61. Epub 2008 Sep 12.
Ref 537002Neurotensin inversely modulates maternal aggression. Neuroscience. 2009 Feb 18;158(4):1215-23. Epub 2008 Dec 7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.